Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancer-Reference-Cited by-同舟云学术

Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancer

Published:2021-01-01 Issue:1 Volume:13 Page:
ISSN:1942-0862
Container-title:mAbs
language:en
Short-container-title:mAbs

Author:

Schofield Darren J.¹,Percival-Alwyn Jennifer¹,Rytelewski Mateusz²,Hood John³,Rothstein Raymond²,Wetzel Leslie²,McGlinchey Kelly⁴,Adjei Grace⁵,Watkins Amanda⁵,Machiesky LeeAnn⁶,Chen Weimin⁶,Andrews John¹,Groves Maria¹,Morrow Michelle⁵,Stewart Ross A.⁴⁵,Leinster Andrew⁵,Wilkinson Robert W.⁵,Hammond Scott A.²,Luheshi Nadia⁵,Dobson Claire¹,Oberst Michael²

Affiliation:

1. Antibody Development and Protein Engineering, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK

2. Discovery Biosciences, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA

3. Clinical and Quantitative Pharmacology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK

4. Translational Medicine Department in Oncology R&D, AstraZeneca, Gaithersburg, MD, USA

5. Discovery Biosciences, Oncology R&D, AstraZeneca, Cambridge, UK

6. Analytical Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA

Funder

AstraZeneca

Publisher

Informa UK Limited

Subject

Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/19420862.2020.1857100

Reference47 articles.

1. Cancer immunotherapy using checkpoint blockade

2. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors

3. Immunogenicity of pembrolizumab (pembro) in patients (pts) with advanced melanoma (MEL) and non-small cell lung cancer (NSCLC): Pooled results from KEYNOTE-001, 002, 006, and 010.

4. U.S. Food and Drug Administration. Keytruda® (pembrolizumab) prescribing information. [accessed 2020 Dec 14]. https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf.

5. U.S. Food and Drug Administration. Opdivo® (nivolumab) prescribing information. [accessed 2020 Dec 14]. https://packageinserts.bms.com/pi/pi_opdivo.pdf.

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Selective depletion of tumor-infiltrating regulatory T cells with BAY 3375968, a novel Fc-optimized anti-CCR8 antibody;Clinical and Experimental Medicine;2024-06-10

2. Navigating the landscape of PD-1/PD-L1 imaging tracers: from challenges to opportunities;Frontiers in Medicine;2024-06-07

3. Landscape and Treatment Options of Shapeshifting Small Cell Lung Cancer;Journal of Clinical Medicine;2024-05-26

4. Lymph node and tumor-associated PD-L1+ macrophages antagonize dendritic cell vaccines by suppressing CD8+ T cells;Cell Reports Medicine;2024-01

5. TO MARKET, TO MARKET–2022: MACROMOLECULAR THERAPEUTICS;Medicinal Chemistry Reviews;2023-11-16